Holen Sie sich die Stockscreener-App
9.42
1.62%
0.15
Schlusskurs vom Vortag:
$9.27
Offen:
$9.2
24-Stunden-Volumen:
202.60K
Relative Volume:
0.70
Marktkapitalisierung:
$536.60M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.86M
KGV:
-7.85
EPS:
-1.2
Netto-Cashflow:
$-58.82M
1W Leistung:
-3.58%
1M Leistung:
+26.61%
6M Leistung:
+134.91%
1J Leistung:
+42.30%
1-Tages-Spanne:
$9.00
$9.5325
1-Wochen-Bereich:
$9.00
$10.31
52-Wochen-Spanne:
$2.60
$10.31
Design Therapeutics Inc Stock (DSGN) Company Profile
Firmenname
Design Therapeutics Inc
Sektor
Branche
Telefon
858-293-4900
Adresse
6005 HIDDEN VALLEY ROAD, CARLSBAD
Vergleichen Sie DSGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
9.42 | 528.05M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-03 | Eingeleitet | Craig Hallum | Buy |
| 2025-12-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | Herabstufung | Wedbush | Outperform → Neutral |
| 2023-05-04 | Hochstufung | Goldman | Sell → Neutral |
| 2022-06-10 | Eingeleitet | Wedbush | Outperform |
| 2022-05-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-19 | Eingeleitet | Goldman | Sell |
| 2021-04-20 | Eingeleitet | Goldman | Neutral |
| 2021-04-20 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-20 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Design Therapeutics Inc Aktie (DSGN) Neueste Nachrichten
Analysts Set Design Therapeutics, Inc. (NASDAQ:DSGN) Target Price at $14.00 - Defense World
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Design Therapeutics (NASDAQ:DSGN) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Why retail investors pile into Design Therapeutics Inc. stockJuly 2025 Technicals & High Accuracy Trade Signal Alerts - Newser
Design Therapeutics (NASDAQ:DSGN) Coverage Initiated by Analysts at Craig Hallum - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Rating Upgraded by Leerink Partnrs - Defense World
Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Leerink Partnrs Upgrades Design Therapeutics (NASDAQ:DSGN) to "Strong-Buy" - MarketBeat
How Design Therapeutics Inc. stock reacts to Fed rate cuts2025 Bull vs Bear & Smart Money Movement Tracker - Newser
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress - Investing.com Nigeria
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Leerink Partners upgrades Design Therapeutics stock to Outperform on pipeline progress By Investing.com - Investing.com South Africa
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Design Therapeutics, Inc. (DSGN): Analysts Upgrade to Outperform Amid Positive Price Potential - Stocks Telegraph
Craig-Hallum initiates Design Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Craig-Hallum initiates Design Therapeutics stock with Buy rating - Investing.com
Leerink Upgrades Design Therapeutics to Outperform From Market Perform, Adjusts PT to $14 From $7 - MarketScreener
Will Design Therapeutics Inc. stock deliver shareholder valueWeekly Trend Summary & Risk Managed Investment Strategies - Newser
Design Therapeutics (DSGN) Stock Analysis Report | Financials & Insights - Benzinga
Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer - Yahoo Finance
How Design Therapeutics Inc. stock performs in weak economyNew Guidance & Safe Entry Point Alerts - Newser
Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media
Will Aries Agro Limited Stock Benefit From Industry Trends in YEARSupport Level Holds & Free Double Digit Growth Tips - earlytimes.in
How sustainable is Design Therapeutics Inc. stock dividend payoutWeekly Trend Summary & Breakout Confirmation Alerts - BỘ NỘI VỤ
Design Therapeutics (NASDAQ:DSGN) Trading Up 9%What's Next? - MarketBeat
Why Design Therapeutics Inc. stock is rated strong buyWeekly Market Report & Consistent Income Trade Recommendations - BỘ NỘI VỤ
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Design Therapeutics (Nasdaq: DSGN) to Participate in Piper Sandler and Evercore 2025 Events - Stock Titan
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth - simplywall.st
Design Therapeutics (NASDAQ:DSGN) Sets New 52-Week HighStill a Buy? - MarketBeat
Design Therapeutics upgraded to Outperform from Sector Perform at RBC Capital - MSN
Design Therapeutics spikes as RBC upgrades on an eventful 2026 - MSN
RBC Capital Upgrades Design Therapeutics (DSGN) - Nasdaq
Design Therapeutics, Inc.Common Stock (Nasdaq:DSGN) Stock Quote - Markets Financial Content
Design Therapeutics' Friedreich Ataxia Program Shows Potential, RBC Says - MarketScreener
Design Therapeutics stock up as RBC upgrades (DSGN:NASDAQ) - Seeking Alpha
Nutex Health Posts Strong Q3 Results, Joins PACS Group, Walmart, Cerence And Other Big Stocks Moving Higher On Thursday - Benzinga
Design Therapeutics : DSGN - 24/7 Wall St.
Design Therapeutics stock rating upgraded by RBC Capital on improved outlook - Investing.com Nigeria
RBC Upgrades Design Therapeutics to Outperform From Sector Perform, Boosts Price Target to $13 From $6, Keeps Speculative Risk - MarketScreener
Can Design Therapeutics Inc. stock sustain free cash flow growthJuly 2025 Breakouts & Safe Entry Point Identification - newser.com
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global - openPR.com
Why retail investors favor Design Therapeutics Inc. stockJuly 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Is Design Therapeutics Inc. stock poised for growthTrade Analysis Summary & Safe Swing Trade Setups - newser.com
How to interpret RSI for Design Therapeutics Inc. stock2025 Price Momentum & Fast Gain Stock Trading Tips - newser.com
Can Design Therapeutics Inc. stock sustain institutional interest - newser.com
Analyzing Design Therapeutics Inc. with risk reward ratio chartsJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com
Technical signs of recovery in Design Therapeutics Inc.Weekly Stock Summary & Technical Buy Zone Confirmations - newser.com
Finanzdaten der Design Therapeutics Inc-Aktie (DSGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):